AzTrials
AzTrials

Bone DiseaseCPCNCT02575352

Calcium Phosphate Cement Registry (CPC Registry)

An observational study of Bone Disease and Fracture Bone, run by Graftys SA at 11 sites in 5 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

CPC REGISTRY is a multi-center, international, prospective, open-label, observational study on the use of injectable calcium phosphate cements for the treatment of bone defects in adults. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Bone Disease, Fracture Bone, Bone Cyst
How many people
500 participants
Where
11 sitesin 5 countries
Study dates
May 2015to May 2021
How long will I take part?
24 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients eligible and planned for bone defect treatment who meet predefined criteria in Instructions For Use (IFU) of GRAFTYS®HBS/ GRAFTYS®Quickset.

Who may be able to join

  • Bone skeletal defects that are not intrinsic to the stability of bone structure OR site which can be stabilized
  • Bone defects from surgery, trauma, tumor or cyst
  • Age ≥ 18 years
  • Patient information and signed informed consent form (for data collection)
  • Affiliation to a Social Security System schema (or similar system)

Who cannot join

  • Patients undergoing radiotherapy or chemotherapy
  • Patients with inflammatory bone disease
  • Patients with a calcium metabolism anomaly, severe metabolic disease, vascular or neurological diseases, or immunological deficiencies
  • Bone site which can lead to the product passing into the joint cavities without appropriate controls (visual, arthroscopic, lavage…).
  • Bone site which can lead to the product passing into the meningeal spaces
  • Vertebroplasty and kyphoplasty
Show all 13Show fewer
  • Site infected or one suspected of being so
  • A cranio-maxillofacial defect with a surface area larger than 25 cm2
  • A site exposed to the sinus (lumen) or nasal mucosa
  • Pregnant women (or likely to be) or breast-feeding women
  • Inability to understand the consent and objectives of the study
  • Unable to undergo medical monitoring for geographical, social or psychological reasons
  • Persons who are deprived of liberty or under guardianship

Trial locations and contacts

11 sites in 5 countries.

11 sites in 5 countries

France4 sites, 4 recruiting
  • Hôpital La Timone

    Marseille, 13385

    Sébastien PARRATTE, MD, Prof.

    Sébastien PARRATTE, MD, Prof.

    Recruiting
  • Study site

    Marseille

    Recruiting
  • Study site

    Paris

    Recruiting
  • Study site

    Saint-Louis

    Recruiting

Other trials in France

Germany3 sites, 3 recruiting
  • Study site

    Kiel

    Recruiting
  • Study site

    Ratzeburg

    Recruiting
  • Study site

    Würzburg

    Recruiting

Other trials in Germany

Italy2 sites, 2 recruiting
  • Study site

    Palermo

    Recruiting
  • Study site

    Piacenza

    Recruiting

Other trials in Italy

Martinique1 site, 1 recruiting
  • Study site

    Fort-de-France

    Recruiting

Other trials in Martinique

Switzerland1 site, 1 recruiting
  • Study site

    Yverdon-les-Bains

    Recruiting

Other trials in Switzerland

About this study

Official title: Observational Prospective Multi-center International Study on the Use of Injectable Calcium Phosphate Cements for the Treatment of Bone Defects in Adults.

CPC REGISTRY is a multi-center, international, prospective, open-label, observational study on the use of injectable calcium phosphate cements for the treatment of bone defects in adults. All patients will be treated with any of the two injectable calcium phosphate bone substitutes (GRAFTYS®HBS/GRAFTYS®Quickset or their private labels) according to standard clinical practice and according to the information provided by GRAFTYS manufacturer in respective device Instructions For Use (IFU).

Read the detailed description

The objective of this observational prospective study is to collect safety and performance data relating to the use of injectable Calcium Phosphate Cements "GRAFTYS®HBS/GRAFTYS®Quickset (or their private labels)" in routine clinical practice from various international hospitals. Therefore this observational study will allow to support data about risk management (established at the end of the product development); and to enhance the current clinical evaluation of products with new clinical data (for longer follow-up). The collected data of this observational study will be "non-identifying data". The patient must have signed a Written Consent Form (for data collection) prior to any data being entered into the electronic Case Report Form.

Patients will be followed as per local standard medical practices of the center for two years. Five follow-up visits/phone calls will be collected (at 3 months (+/-14 days), 6 months (+/- 14 days), 9 months (+/-21 days), 12 months (+/- 30 days) and 24 months (+/-60 days)). Each visit/phone call includes the collection of Adverse Events, the measurement of health status (quality of life and functional scores) and the X-ray scoring (if X-ray imaging is available). No additional exams (other than the routine clinical practice) are requested. The surgeons have to follow their usual practices (e.g. X-Rays have to be performed only if they are scheduled in the routine clinical practice).

All Adverse Events will be collected and monitored at each follow-up visit or follow-up phone call. All Serious Adverse Events must be described via a Serious Adverse Event form in e-CRF and all Adverse Device Effects must be described via a "Product Complaint Form" in e-CRF.

Descriptive analyses will be performed in order to describe: nature of adverse events, their distribution and frequency. Moreover, all factors which may appear predictive for the rate of adverse events will be analyzed (age, sex, amount of CPC injected, delivery system used, diabetes history, smoking habits, alcohol consumption, concomitant treatments/diseases…). For all time-dependent events, life-tables will be able to calculate using the Kaplan Meier estimate method, for a period starting on the date of the procedure up to and including the 24-months follow-up visit.

Keywords
Bone Substitute, Calcium Phosphate Cement, GRAFTYS, GRAFTYS®HBS, GRAFTYS®QUICKSET, Bone void filler, Bone growth, Registry, Bone defect, Revision arthroplasty, Arthrodesis
Medical subject headings
Bone Diseases, Fractures, Bone, Bone Cysts, Ankylosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse Device Effect rate

    Rate of Adverse Events related to bone substitutes (registry devices) for the follow-up period of patients.

    Measured: For 24 months

Secondary outcomes (26)
  1. Technical Success rate

    Technical Success rate defined as successful delivery of the bone substitute in the target defect bone without evidence of delivery device or bone substitute malfunction. (NOTE: Malfunction is definied as a failure of the medical device to perform in accordance with its intended purpose when used in accordance with the Instructions For Uses (IFU)).

    Measured: At surgical procedure

  2. Device Deficiencies rate

    Device deficiency is defined as an inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance.

    NOTE: Device deficiencies include malfunctions, use errors, and inadequate labelling.

    Measured: At surgical procedure

  3. Serious Adverse Events rate in the peroperative period

    Serious Adverse Event is defined as any adverse event that:

    1. Led to a death,
    2. Led to serious deterioration in health of the subject that either resulted in:
    3. a life-threatening illness or injury, or
    4. a permanent impairment of a body structure or a body function, or
    5. in-patient or prolonged hospitalization, or
    6. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
    7. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Measured: At surgical procedure

  4. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that:

    1. Led to a death,
    2. Led to serious deterioration in health of the subject that either resulted in:
    3. a life-threatening illness or injury, or
    4. a permanent impairment of a body structure or a body function, or
    5. in-patient or prolonged hospitalization, or
    6. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
    7. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Measured: 3 months post index procedure

  5. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that:

    1. Led to a death,
    2. Led to serious deterioration in health of the subject that either resulted in:
    3. a life-threatening illness or injury, or
    4. a permanent impairment of a body structure or a body function, or
    5. in-patient or prolonged hospitalization, or
    6. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
    7. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Measured: 6 months post index procedure

  6. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that:

    1. Led to a death,
    2. Led to serious deterioration in health of the subject that either resulted in:
    3. a life-threatening illness or injury, or
    4. a permanent impairment of a body structure or a body function, or
    5. in-patient or prolonged hospitalization, or
    6. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
    7. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Measured: 9 months post index procedure

  7. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that:

    1. Led to a death,
    2. Led to serious deterioration in health of the subject that either resulted in:
    3. a life-threatening illness or injury, or
    4. a permanent impairment of a body structure or a body function, or
    5. in-patient or prolonged hospitalization, or
    6. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
    7. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Measured: 12 months post index procedure

  8. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that:

    1. Led to a death,
    2. Led to serious deterioration in health of the subject that either resulted in:
    3. a life-threatening illness or injury, or
    4. a permanent impairment of a body structure or a body function, or
    5. in-patient or prolonged hospitalization, or
    6. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
    7. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Measured: 24 months post index procedure

  9. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Measured: 3 months post index procedure

  10. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Measured: 6 months post index procedure

  11. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Measured: 9 months post index procedure

  12. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Measured: 12 months post index procedure

  13. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Measured: 24 months post index procedure

  14. Quality of life score at baseline (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Measured: At baseline (pre-operative)

  15. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Measured: 3 months post index procedure

  16. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Measured: 6 months post index procedure

  17. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Measured: 9 months post index procedure

  18. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Measured: 12 months post index procedure

  19. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Measured: 24 months post index procedure

  20. Functional score at baseline (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:

    • Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
    • Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
    • Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
    • Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Measured: At baseline (pre-operative)

  21. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:

    • Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
    • Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
    • Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
    • Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Measured: 3 months post index procedure

  22. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:

    • Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
    • Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
    • Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
    • Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Measured: 6 months post index procedure

  23. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:

    • Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
    • Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
    • Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
    • Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Measured: 9 months post index procedure

  24. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:

    • Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
    • Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
    • Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
    • Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Measured: 12 months post index procedure

  25. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:

    • Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand).
    • Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form)
    • Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form)
    • Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Measured: 24 months post index procedure

  26. Surgeon's Satisfaction survey with registry device

    Surgeon's Satisfaction survey with registry device (about mixing ability, injecting ability and moldability) thanks to a 100-mm Visual Analog Scale (VAS). A score of zero indicated absolutely inacceptable, while a score of 100 indicated very satisfying.

    Measured: At surgical procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Oct 2015 (estimated)
  2. Study startMay 2015
  3. Primary completionMay 2021 (estimated)
  4. Study completionMay 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
500 participants (estimated)
Target duration
24 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT02575352
Sponsor's protocol ID
GR-NI-INJ
Acronym
CPC
Status last verified
May 2018
First submitted
12 Oct 2015
Last updated
25 May 2018
Results posted
No
Data monitoring committee
No

Publications

  • Hoelscher-Doht S, Ewald A, Fuchs A, Otto P, Bator J, Grunz JP, Kneist K, Bogelein L, Gbureck U. Osteointegration and remodeling of a novel mineral magnesium phosphate-based bone glue in-vivo. J Biomater Appl. 2025 Jul;40(1):82-91. doi: 10.1177/08853282251326033. Epub 2025 Mar 14.

    PubMed 40083317

Questions about this trial

What is this clinical trial studying?

An observational study of Bone Disease and Fracture Bone, run by Graftys SA at 11 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 May 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 11 sites in France, Germany, Italy, Martinique, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mehan ALTAIFI (+33(0) 442 603 000, mehan.altaifi@graftys.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse Device Effect rate (time frame: For 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02575352, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2018; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in